和誉-B(02256)今日盘中股价大幅上涨5.83%，引起了市场的广泛关注。
消息面上，公司宣布其口服小分子KRAS G12D抑制剂ABSK141已在针对晚期实体瘤患者的I/II期临床试验中成功完成首例患者给药，这标志着公司在KRAS靶向治疗领域取得重要里程碑，增强了市场对其研发管线进展的乐观预期。此外，公司创始人兼主席徐耀昌博士于近期在公开市场增持公司股份，也向市场传递了内部人士对公司未来发展的信心。
ABSK141是一种针对KRAS G12D突变的高选择性抑制剂，该突变常见于胰腺癌、结直肠癌等多种实体瘤中，目前尚无获批的靶向疗法，因此其临床进展备受关注。此次临床试验已获得美国FDA和中国NMPA的批准，顺利推进至患者给药阶段。同时，徐耀昌博士的增持行为进一步巩固了其持股比例，显示了管理层对公司价值的认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.